Skip to content
OpenCapital
Get started

Astrana Health ASTH Stock Issued During Period Shares Merger

Other financials

Income statement

See full
Revenue$965.1M+55.6%
Gross profit$105.7M+48.2%
Operating income$28.5M+38.6%
Net income$14.4M+116%
EPS (diluted)$0.29+107%

Balance sheet

See full
Cash & equivalents$478.4M+85.0%
Total debt$1.1B+136%
Total equity$800.3M+7.4%
Total assets$2.4B+77.2%

Cash flow

See full
Operating cash flow$68.1M+309%
CapEx$4.0M+30.3%
Free cash flow$64.1M+372%

Valuation

See full
Market cap$2.1B-3.0%

Profitability

See full
Gross margin10.7%-1.3pp
Operating margin2.5%-1.1pp
Net margin0.9%—
FCF margin4.6%—

Returns & leverage

See full
Return on equity3.9%—
Debt / equity1.3×+0.7×
Current ratio1.3×-0.4×

Where this comes from

Reported directly by Astrana Health in its filing.

Tagged under the XBRL concept asth:StockIssuedDuringPeriodSharesMerger.

The official record: Astrana Health’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Astrana Health's stock issued during period shares merger?
Astrana Health (ASTH) reported stock issued during period shares merger of 41K in Q1 2026.